Our Oncology Clinical Strategy is designed to transform survival

Home / Our therapy areas / Oncology / Clinical Strategy

At AstraZeneca, we think differently about the underlying genetic causes of cancer. Our clinical strategy aims to transform survival by seeking to combat metastatic and resistant disease and providing options to treat early. We are defining new biomarkers and therapeutic targets that cut across multiple tumour types. We are transforming the way people with cancer are diagnosed and treated by looking in new places, beyond traditional classifications and focusing on the properties of a tumour, not just its type.

Introduction to our clinical strategy

Our clinical stratgy is designed to transform survival. We aim to combat cancer at all stages, but we know that the earlier we can detect and address cancer, the closer we may be to better outcomes.

Trending stories

Latest Oncology News

Imfinzi granted Priority Review in the US for patients with muscle-invasive bladder cancer
  • Corporate Press Release
Imfinzi approved in the US as first and only immunotherapy regimen for patients with limited-stage small cell lung cancer
  • Corporate Press Release
Truqap combination in PTEN-deficient metastatic hormone-sensitive prostate cancer demonstrated statistically significant and clinically meaningful improvement in radiographic progression-free survival in CAPItello-281 Phase III trial
  • Corporate Press Release
Tagrisso recommended for approval in the EU by CHMP for patients with unresectable EGFR-mutated lung cancer
  • Corporate Press Release
Datopotamab deruxtecan new BLA submitted for accelerated approval in the US for patients with previously treated advanced EGFR-mutated non-small cell lung cancer
  • Corporate Press Release
AstraZeneca showcases strength of haematology portfolio and pipeline at ASH 2024
  • Corporate Press Release
View all news and press releases

Explore our Oncology pillars

Medicines: Portfolio and Pipeline

With our portfolio, our pipeline and our people, we aim to revolutionise cancer care.

Patient Experience

We are catalysing changes in the practice of medicine to transform the patient experience.

Our People & Culture

Our people, passion and innovation drive us.